营养药品 CDMO 市场 - 全球产业规模、份额、趋势、机会和预测，按剂型、服务、公司规模、地区和竞争细分，2019-2029 年

2023 年，全球营养保健品CDMO 市场估值为340.9 亿美元，预计到2029 年的预测期内复合年增长率将达到7.87%。公司。营养保健品是结合了食品和药物成分的产品，旨在提供基本营养以外的健康益处。 CDMO 是一家为製药、生技和营养保健品公司提供服务，帮助开发、製造、有时甚至行销其产品的公司。 CDMO 提供专业知识、设施和资源，在产品生命週期的各个阶段（从研发到製造和分销）为客户提供协助。营养保健品 CDMO」可能是指专门提供与营养保健品开发、配方、测试和製造相关的服务的合约开发和製造组织。这可能包括产品配方、品质控制、法规遵从性和生产等服务的营养补充剂。

市场概况
预测期	2025-2029
2023 年市场规模	340.9亿美元
2029 年市场规模	532亿美元
2024-2029 年复合年增长率	7. 87%
成长最快的细分市场	片剂和胶囊
最大的市场	北美洲

主要市场驱动因素

对营养保健产品的需求不断增长推动市场成长

慢性病盛行率的增加推动了市场的成长

主要市场挑战

品质控制和保证

环境永续性

主要市场趋势

个性化营养的兴起

研究和开发的进步推动市场成长

细分市场洞察

剂型见解

服务洞察

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球保健品 CDMO 市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按剂型（片剂和胶囊、粉末、软胶囊、其他）
  • 按服务（产品配方和开发、製造和包装、研究与开发 (R&D)、法规合规性、其他）
  • 依公司规模（小型公司、中型公司、大型公司）
  • 按公司划分 (2023)
  • 按地区
• 市场地图

第 6 章：北美营养药品 CDMO 市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依剂型分类
  • 按服务
  • 按公司规模
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第 7 章：欧洲营养药品 CDMO 市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依剂型分类
  • 按服务
  • 按公司规模
  • 按国家/地区
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第 8 章：亚太营养保健品 CDMO 市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依剂型分类
  • 按服务
  • 按公司规模
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第 9 章：南美洲营养药品 CDMO 市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依剂型分类
  • 按服务
  • 按公司规模
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲营养药品 CDMO 市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依剂型分类
  • 按服务
  • 按公司规模
  • 按国家/地区
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

• 最近的发展
• 产品发布
• 併购

第 13 章：大环境分析

第 14 章：波特的五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第15章：竞争格局

• Catalent Inc.
• Lonza Group AG
• NUTRASCIENCE LABS Inc
• Robinson Pharma, Inc.
• Health Wright Products, Inc.
• Innovations in Nutrition + Wellness
• INPHARMA SpA
• Aenova Group
• NutraPakUSA
• SFI Health Pty Ltd.

第 16 章：策略建议

第17章调查会社について・免责事项

Global Nutraceuticals CDMO Market was valued at USD 34.09 Billion in 2023 and is anticipated to projected at an impressive CAGR 7.87% growth in the forecast period through 2029. Nutraceuticals CDMO is a company that provides development and manufacturing services to nutraceutical companies. Nutraceuticals are products that combine food and pharmaceutical components and are intended to provide health benefits beyond basic nutrition. A CDMO is a company that provides services to pharmaceutical, biotechnology, and nutraceutical companies to help develop, manufacture, and sometimes even market their products. CDMOs offer specialized expertise, facilities, and resources to assist clients in various stages of the product lifecycle, from research and development to manufacturing and distribution. Nutraceuticals CDMO" could potentially refer to a contract development and manufacturing organization that specializes in providing services related to the development, formulation, testing, and manufacturing of nutraceutical products. This could include services such as product formulation, quality control, regulatory compliance, and production of nutraceutical supplement.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 34.09 Billion
Market Size 2029	USD 53.20 Billion
CAGR 2024-2029	7. 87%
Fastest Growing Segment	Tablets & Capsules
Largest Market	North America

Key Market Drivers

Growing Demand for Nutraceutical Products Drives the Market Growth

The growing demand for nutraceutical products plays a significant role in driving the growth of the Global Nutraceutical CDMO (Contract Development and Manufacturing Organization) market. As consumer interest in nutraceuticals continues to rise, there is a greater need for innovative and differentiated products. Nutraceutical companies often require specialized expertise to develop and formulate new products that meet consumer preferences and health needs. Nutraceutical CDMOs offer research and development capabilities to help companies create novel formulations, leading to a wider variety of nutraceutical products in the market. High demand for nutraceutical products necessitates the scaling up of manufacturing capacities. Nutraceutical CDMOs have the infrastructure and expertise to efficiently manufacture products in larger quantities, meeting the needs of both established and emerging nutraceutical brands. The nutraceutical industry is subject to stringent regulatory requirements to ensure product safety and efficacy. Nutraceutical CDMOs possess expertise in navigating complex regulatory frameworks and ensuring compliance. As demand grows, more nutraceutical companies seek the services of CDMOs to ensure their products meet regulatory standards, leading to an increased demand for CDMO services. The competitive nature of the nutraceutical market requires rapid product development and market entry. Nutraceutical CDMOs offer streamlined processes and established supply chains that can accelerate product development and commercialization. This enables nutraceutical companies to capitalize on market demand more quickly. Nutraceutical companies may choose to outsource certain aspects of their operations, such as formulation, testing, and manufacturing, to CDMOs. This allows these companies to focus on their core competencies, such as marketing, branding, and distribution. By partnering with CDMOs, nutraceutical brands can efficiently bring products to market while focusing on their unique strengths.

Increasing Prevalence of Chronic Diseases Drives the Market Growth

The increasing prevalence of chronic diseases is a significant driver for the growth of the Global Nutraceutical CDMO (Contract Development and Manufacturing Organization) market. Chronic diseases such as cardiovascular diseases, diabetes, obesity, and neurodegenerative disorders are often linked to lifestyle factors and poor dietary choices. Consumers are becoming more proactive about their health, seeking preventive measures to mitigate the risk of chronic diseases. Nutraceutical products, with their potential health benefits, are being viewed as a part of preventive healthcare strategies. Nutraceutical CDMOs play a key role in developing and manufacturing these products to meet the growing demand. Nutraceuticals are increasingly being recognized for their potential therapeutic benefits in managing chronic diseases. Nutrients, bioactive compounds, and herbal extracts found in nutraceutical products have been studied for their positive effects on disease management and symptom relief. Nutraceutical CDMOs collaborate with pharmaceutical and nutraceutical companies to develop specialized products targeting specific chronic conditions. Different chronic diseases may require tailored nutritional approaches. Nutraceutical CDMOs are equipped to develop customized formulations and delivery systems that address the specific needs of individuals dealing with chronic diseases. This level of personalization and customization enhances the effectiveness of nutraceutical products in supporting disease management. The effectiveness of nutraceuticals in managing chronic diseases is often supported by clinical research and trials. Nutraceutical CDMOs can assist companies in designing and conducting clinical studies to validate the health benefits of their products. This scientific validation is crucial for gaining consumer trust and regulatory approval.

Key Market Challenges

Quality Control and Assurance

Quality control and assurance pose significant challenges to the Global Nutraceutical CDMO (Contract Development and Manufacturing Organization) market due to the complexity and critical nature of ensuring consistent product quality and safety. Nutraceutical products are subject to regulatory standards that ensure their safety, efficacy, and accurate labelling. Compliance with diverse and evolving regulations in different regions can be complex and time-consuming. Nutraceutical CDMOs must stay up to date with changing regulations and adapt their processes accordingly. Nutraceuticals often involve complex formulations containing multiple active ingredients. Ensuring consistent quality and potency across batches requires precise formulation techniques, thorough mixing, and rigorous testing. Variability in ingredient characteristics can complicate the process. Natural ingredients used in nutraceuticals can vary in quality, potency, and composition due to factors such as seasonal variations, growing conditions, and sourcing. Nutraceutical CDMOs must carefully select suppliers and establish stringent quality standards to minimize variability.

Environmental Sustainability

Environmental sustainability poses a significant challenge to the Global Nutraceutical CDMO (Contract Development and Manufacturing Organization) market, as the industry seeks to balance business growth with responsible environmental practices. Many nutraceutical ingredients are derived from natural sources, and their extraction can have environmental impacts, such as deforestation, habitat destruction, and overharvesting. Sustainable sourcing practices are essential to ensure the long-term availability of these ingredients and to minimize negative ecological effects. The collection of certain botanicals and natural ingredients may threaten local plant and animal species. Nutraceutical CDMOs must consider the potential impacts on biodiversity and ecosystems and work to support conservation efforts. Nutraceutical manufacturing processes can generate waste, including packaging materials, byproducts, and unused ingredients. Minimizing waste through efficient production, recycling, and responsible disposal practices is crucial for reducing environmental impact. Packaging materials used for nutraceutical products, such as bottles, containers, and labels, can contribute to plastic waste. Nutraceutical CDMOs must explore sustainable packaging alternatives, reduce plastic usage, and promote recycling. Manufacturing processes, equipment operation, and facility maintenance contribute to energy consumption and greenhouse gas emissions. Nutraceutical CDMOs can adopt energy-efficient technologies and renewable energy sources to reduce their carbon footprint.

Key Market Trends

Rise of Personalized Nutrition

The rise of personalized nutrition is a significant trend in the Global Nutraceutical CDMO (Contract Development and Manufacturing Organization) market, shaping how nutraceutical products are developed, formulated, and manufactured. Personalized nutrition involves tailoring dietary and supplement recommendations to an individual's unique health needs, genetic makeup, lifestyle, and preferences. Nutraceutical CDMOs play a critical role in developing customized formulations that align with the specific requirements of each consumer. This trend requires CDMOs to possess the expertise to create diverse and flexible formulations that can be adjusted based on individual factors. Personalized nutrition relies on comprehensive health assessments, biomarker analysis, and genetic testing to determine an individual's nutritional needs. Nutraceutical CDMOs may collaborate with testing laboratories and healthcare professionals to incorporate these data into the formulation process, ensuring that the final product aligns with the consumer's specific health goals. Personalized nutrition often involves the integration of data from wearable devices, health apps, and genetic profiling. Nutraceutical CDMOs may collaborate with digital health companies to create products that complement data-driven health management strategies. This could involve combining nutraceuticals with digital tools for personalized tracking and monitoring. Customized formulations may require specialized delivery systems to optimize nutrient absorption and bioavailability based on individual needs. Nutraceutical CDMOs can leverage advanced delivery technologies, such as encapsulation and nanotechnology, to create personalized products with enhanced efficacy.

Advancements in Research and Development Drives the Market Growth

Advancements in research and development (R&D) play a crucial role in driving the growth of the Global Nutraceutical CDMO (Contract Development and Manufacturing Organization) market. Advancements in R&D lead to the discovery of novel ingredients, formulations, and delivery systems for nutraceutical products. Nutraceutical CDMOs collaborate with nutraceutical companies to translate these innovations into market-ready products. CDMOs provide the necessary expertise to develop, test, and manufacture new and innovative nutraceutical offerings. R&D advancements result in a deeper understanding of the health benefits and mechanisms of action of various nutrients and bioactive compounds. Nutraceutical CDMOs facilitate the integration of scientific research into product development, helping companies create evidence-based nutraceuticals that have been clinically validated and substantiated. As R&D reveals the potential synergies between different nutrients and compounds, nutraceutical formulations become more sophisticated. Nutraceutical CDMOs specialize in formulating complex blends of ingredients, ensuring precise ratios and optimal synergistic effects. This expertise is crucial for creating effective and well-balanced nutraceutical products. Advancements in R&D allow for a better understanding of specific health concerns and conditions that nutraceuticals can address. Nutraceutical CDMOs collaborate with nutraceutical companies to develop targeted health solutions, tailoring products to address specific health needs and wellness trends identified through scientific research. Advances in R&D enable a deeper understanding of individual nutritional needs based on genetics, lifestyle, and health status. Nutraceutical CDMOs work with nutraceutical companies to develop personalized nutrition solutions, creating products that cater to the unique requirements of each consumer.

Segmental Insights

Dosage Form Insights

In 2023, the Nutraceuticals CDMO market was dominated by the tablets & capsules segment and is predicted to continue expanding over the coming years. Tablets and capsules are among the most dominant dosage forms in the Global Nutraceutical CDMO (Contract Development and Manufacturing Organization) market. Tablets and capsules are convenient and easy for consumers to consume. They can be taken with water or other liquids, making them suitable for a wide range of consumers, including those with swallowing difficulties. Tablets and capsules allow for precise dosing, ensuring that consumers receive the intended amount of active ingredients in each dose. This is especially important for nutraceutical products, where consistent dosing is crucial for achieving desired health benefits. Tablets and capsules offer excellent stability and protection for the enclosed ingredients. The solid dosage form helps protect sensitive compounds from moisture, light, and air, which can contribute to longer shelf life and product potency.

Service Insights

In 2023, the Nutraceuticals CDMO market was dominated by manufacturing and packing segment and is predicted to continue expanding over the coming years. Manufacturing and packaging services are two key service forms that dominate the Global Nutraceutical CDMO (Contract Development and Manufacturing Organization) market. Manufacturing services encompass the production of nutraceutical products, including dietary supplements, functional foods, and other health and wellness products. Nutraceutical CDMOs offer a range of manufacturing capabilities to meet the diverse needs of their clients: Formulation Development, Ingredient Sourcing, Manufacturing Processes, Quality Control and Testing, Scalability. Packaging services involve the design, labeling, and packaging of nutraceutical products for retail or distribution. Effective packaging is crucial for product differentiation, consumer communication, and regulatory compliance: Packaging Design, Labeling Compliance, Bottling and Filling, Shrink Wrapping and Sealing, Batch Coding and Serialization.

Regional Insights

The North America region has established itself as the leader in the Global Nutraceuticals CDMO Market in 2023. The North American nutraceutical market, particularly in the United States, has a long history of consumer acceptance and adoption of dietary supplements and functional foods. This maturity has led to a strong demand for CDMO services to develop and manufacture a wide range of nutraceutical products. North America, especially the United States, has established regulatory frameworks for dietary supplements and nutraceutical products. Nutraceutical CDMOs in the region are well-versed in these regulations, ensuring that products are developed, manufactured, and labeled in compliance with applicable laws. North American consumers are increasingly conscious of health and wellness, driving the demand for nutraceutical products. This high demand prompts nutraceutical companies to seek CDMOs that can help them meet consumer needs by offering innovative formulations and efficient manufacturing processes.

Key Market Players

Catalent Inc.

Lonza Group AG

NUTRASCIENCE LABS Inc

Robinson Pharma, Inc.

Health Wright Products, Inc.

Innovations in Nutrition + Wellness

INPHARMA S.p.A.

Aenova Group

NutraPak USA

SFI Health Pty Ltd.

Report Scope:

In this report, the Global Nutraceuticals CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nutraceuticals CDMO Market, By Dosage Form:

Tablets & Capsules Powder Softgel Others

Nutraceuticals CDMO Market, By Service:

Product Formulation and Development Manufacturing and Packaging Research & Development (R&D) Regulatory Compliance Others

Nutraceuticals CDMO Market, By Company Size:

Small Companies Mid-Sized Companies Large Companies

Nutraceuticals CDMO Market, By region:

North America
• United States
• Canada
• Mexico
Asia-Pacific
• China
• India
• South Korea
• Australia
• Japan
Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
South America
• Brazil
• Argentina
• Colombia
Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Nutraceuticals CDMO Market.

Available Customizations:

Global Nutraceuticals CDMO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nutraceuticals CDMO Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Dosage Form (Tablets & Capsules, Powder, Softgel, Others)
  • 5.2.2. By Service (Product Formulation and Development, Manufacturing and Packaging, Research & Development (R&D), Regulatory Compliance, Others)
  • 5.2.3. By Company Size (Small Companies, Mid-Sized Companies, Large Companies)
  • 5.2.4. By Company (2023)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Nutraceuticals CDMO Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Dosage Form
  • 6.2.2. By Service
  • 6.2.3. By Company Size
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Nutraceuticals CDMO Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value Service
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Dosage Form
      • 6.3.1.2.2. By Service
      • 6.3.1.2.3. By Company Size
  • 6.3.2. Mexico Nutraceuticals CDMO Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value Service
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Dosage Form
      • 6.3.2.2.2. By Service
      • 6.3.2.2.3. By Company Size
  • 6.3.3. Canada Nutraceuticals CDMO Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value Service
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Dosage Form
      • 6.3.3.2.2. By Service
      • 6.3.3.2.3. By Company Size

7. Europe Nutraceuticals CDMO Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Dosage Form
  • 7.2.2. By Service
  • 7.2.3. By Company Size
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Nutraceuticals CDMO Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value Service
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Dosage Form
      • 7.3.1.2.2. By Service
      • 7.3.1.2.3. By Company Size
  • 7.3.2. Germany Nutraceuticals CDMO Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value Service
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Dosage Form
      • 7.3.2.2.2. By Service
      • 7.3.2.2.3. By Company Size
  • 7.3.3. United Kingdom Nutraceuticals CDMO Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value Service
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Dosage Form
      • 7.3.3.2.2. By Service
      • 7.3.3.2.3. By Company Size
  • 7.3.4. Italy Nutraceuticals CDMO Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value Service
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Dosage Form
      • 7.3.4.2.2. By Service
      • 7.3.4.2.3. By Company Size
  • 7.3.5. Spain Nutraceuticals CDMO Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value Service
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Dosage Form
      • 7.3.5.2.2. By Service
      • 7.3.5.2.3. By Company Size

8. Asia-Pacific Nutraceuticals CDMO Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Dosage Form
  • 8.2.2. By Service
  • 8.2.3. By Company Size
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Nutraceuticals CDMO Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value Service
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Dosage Form
      • 8.3.1.2.2. By Service
      • 8.3.1.2.3. By Company Size
  • 8.3.2. India Nutraceuticals CDMO Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value Service
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Dosage Form
      • 8.3.2.2.2. By Service
      • 8.3.2.2.3. By Company Size
  • 8.3.3. South Korea Nutraceuticals CDMO Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value Service
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Dosage Form
      • 8.3.3.2.2. By Service
      • 8.3.3.2.3. By Company Size
  • 8.3.4. Japan Nutraceuticals CDMO Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value Service
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Dosage Form
      • 8.3.4.2.2. By Service
      • 8.3.4.2.3. By Company Size
  • 8.3.5. Australia Nutraceuticals CDMO Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value Service
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Dosage Form
      • 8.3.5.2.2. By Service
      • 8.3.5.2.3. By Company Size

9. South America Nutraceuticals CDMO Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Dosage Form
  • 9.2.2. By Service
  • 9.2.3. By Company Size
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Nutraceuticals CDMO Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value Service
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Dosage Form
      • 9.3.1.2.2. By Service
      • 9.3.1.2.3. By Company Size
  • 9.3.2. Argentina Nutraceuticals CDMO Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value Service
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Dosage Form
      • 9.3.2.2.2. By Service
      • 9.3.2.2.3. By Company Size
  • 9.3.3. Colombia Nutraceuticals CDMO Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value Service
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Dosage Form
      • 9.3.3.2.2. By Service
      • 9.3.3.2.3. By Company Size

10. Middle East and Africa Nutraceuticals CDMO Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Dosage Form
  • 10.2.2. By Service
  • 10.2.3. By Company Size
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Nutraceuticals CDMO Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value Service
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Dosage Form
      • 10.3.1.2.2. By Service
      • 10.3.1.2.3. By Company Size
  • 10.3.2. Saudi Arabia Nutraceuticals CDMO Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value Service
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Dosage Form
      • 10.3.2.2.2. By Service
      • 10.3.2.2.3. By Company Size
  • 10.3.3. UAE Nutraceuticals CDMO Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value Service
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Dosage Form
      • 10.3.3.2.2. By Service
      • 10.3.3.2.3. By Company Size

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Catalent Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (In case of listed companies)
  • 15.1.5. Recent Developments
  • 15.1.6. SWOT Analysis
• 15.2. Lonza Group AG
• 15.3. NUTRASCIENCE LABS Inc
• 15.4. Robinson Pharma, Inc.
• 15.5. Health Wright Products, Inc.
• 15.6. Innovations in Nutrition + Wellness
• 15.7. INPHARMA S.p.A.
• 15.8. Aenova Group
• 15.9. NutraPakUSA
• 15.10. SFI Health Pty Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer